Carlsmed’s stock has dipped 6% since its IPO, but Goldman Sachs thinks there’s a 35% upside. The buzz? Carlsmed’s tech could make spine surgeries smarter and more personal, and hospitals are about to get paid more for using their implants. Still, most regular investors aren’t buying the hype yet. If you’re into picking stocks with big potential, this could be one to keep an eye on for your next coffee break chat. #Business #Market #stocks